share_log

Brookline Capital Reiterates Buy on Adial Pharmaceuticals, Maintains $6 Price Target

Benzinga ·  Jul 12, 2023 05:59

Brookline Capital analyst Kumaraguru Raja reiterates Adial Pharmaceuticals (NASDAQ:ADIL) with a Buy and maintains $6 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment